Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. - Wikidata - wikimedia - TriplyDB

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

http://www.wikidata.org/entity/Q33338535

about

Gemcitabine and platinum combinations in pancreatic cancer.Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer Evolution of systemic therapy for advanced pancreatic cancer.MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function Pancreatic cancer: the evolving role of systemic therapy.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Developments in the systemic therapy of pancreatic cancer.Randomized phase II trials: a long-term investment with promising returns Advanced pancreatic cancer: is there a role for combination therapy?Review article: chemotherapy for pancreatic cancer.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.Gemcitabine in the treatment of metastatic pancreatic cancer.The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.A comparison of phase II study strategies.CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.

P2860

Q33344048-90792E22-BB48-4412-AC2E-37C14DD27E7B Q33389637-CBEE7B43-94AF-4C62-837D-68C49D52C633 Q33409519-CDF8D15C-919C-433E-AFBA-F9EC96A6366A Q33428016-7C567D09-CDA8-4937-B748-0C0C37B8FC7C Q33557413-DEAB9091-89F9-45ED-9697-C14C003F7FEB Q33930068-34CE99DD-8DDD-4223-AAFD-7A63B86ED10F Q34515547-06BD8AC2-7D9D-4E6A-B7E0-B2582A46055F Q34665177-443A01F3-4A1D-4D0A-B1F5-6BC4C7FFF571 Q34810745-C867C9E3-E94F-42ED-9648-EAA95BF3A1BA Q34818494-428842B8-9619-4650-80BF-957E00C9B63A Q35087326-C28DE5AE-BCAA-42DC-87C2-368BBE74E414 Q35115259-05786500-435E-4180-9CAF-31833C7D3197 Q35576200-3DCE9EA0-A526-4839-A400-DAF535B16144 Q35599597-5D8A4BD3-DEA7-4155-9635-174A51646108 Q35776091-3B633C87-7CEA-4760-A7F2-2ED244093B7F Q36384541-67AE779F-02C9-4D5B-BAA4-3746494FDB40 Q36476666-A222AB9C-9F10-4A62-87C0-9EAAE8EE6546 Q36831339-FD4CB6CE-4AA3-48A9-A6D5-5343EC0B09AB Q36831348-478BEA61-8526-4A5E-9ECF-A96B2B0CBEA9 Q37134412-D8A50074-2451-4B05-8398-DEA9B39757AD Q37235527-3039553A-C29F-47A8-BD06-7DD61618CF49 Q37375886-CB68D8F1-9251-4294-8ACC-E671E4F3A10B Q37398718-4D968772-D878-42F2-8712-C3016C76FB7E Q39016327-EB060DE2-C6D4-4EED-970A-47D461BC2AFA Q39022032-B9ACF720-C811-4AD0-87F4-F4123FC066E4 Q39466674-67F6FCBD-CE2D-4BB1-9862-C36C45FE82AB Q44906700-D6320C19-F9B5-44B5-83F2-9D963C96C7B3 Q46845221-75304C3A-87EA-4D1E-9F36-243C552387B3

P2860

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

http://www.wikidata.org/entity/Q33338535

description

2001 nî lūn-bûn

@nan

2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@ast

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@en

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@nl

type

label

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@ast

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@en

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@nl

prefLabel

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@ast

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@en

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@nl

P1433

Q33338535-A4FBFF62-995E-48DB-A078-05E4A89965B5

P1476

Q33338535-9F4FD6CC-4150-489A-A17A-B1EC0DDB67F8

P2093

Q33338535-403C1CB3-FB2D-4CA3-81C6-18AD6B5E2E03

Q33338535-4DFB9CBA-6D34-4994-97A7-990FE214D8FE

Q33338535-57B0C42F-F03C-40A7-94F1-34D6B1290286

Q33338535-5CDD2FF9-A798-4E32-87A3-3B7F94E4C06C

Q33338535-604AC976-5DA5-48AC-82A2-8A0D1E4B2A3C

Q33338535-8C1A81B2-CC63-44B2-A034-2CD0E8EECDEF

Q33338535-CB31F994-D120-4E18-BA53-10F03333B5F2

Q33338535-E2F28783-4077-4C16-9A38-AD4EE603B1C7

Q33338535-FA29ECFF-E3B4-427A-A623-BFED13DBDC8D

P2860

Q33338535-061D1AE5-E92C-439E-A131-2C1024A35E1F

Q33338535-0D3F90DD-0632-4493-A908-1370AE210104

Q33338535-211B5B12-20C3-420F-A275-131F668C163E

Q33338535-25874627-14DA-426E-BC7C-B2F4F526E74B

Q33338535-2770AD78-26B6-4157-BBBC-720FE23DBED4

Q33338535-4AA40BCA-68AC-4FFF-B20F-481174DB74E5

Q33338535-5FCCFF45-A5C8-4261-9E18-A9285F89D6F8

Q33338535-600FF97C-28D7-4977-9F92-F38FF3A2671C

Q33338535-666E2326-723B-4119-AFB9-00C7616AD8CE

Q33338535-97F4303C-0316-47B2-B605-DBBB0B43DB20

P304

Q33338535-A1744AF0-AA10-4F46-9DA2-038E796E7E0D

P31

Q33338535-F72FE0B2-8E91-41E6-9884-C8E29FA4C324

P356

Q33338535-F2C45380-BBC3-4DDF-AED6-E7EA649837F2

P407

Q33338535-95394F87-D1BB-4EE8-A910-33B658508953

P433

Q33338535-0D7ED42B-DB5C-4DF9-A2C4-9DA221AF393C

P478

Q33338535-A1CA36E7-4FE3-4653-8A33-7D6F37149BEF

P577

Q33338535-EAE4CE7B-DE2D-4F5E-9B8E-070D904065D6

P698

Q33338535-DC4FB52B-73B8-4EEB-A92E-BDA3627D184F

P921

Q33338535-331B2DD3-0F3D-43AB-BF08-F6707D37A1A3

P356

1097-0142(20010801)92:3%3C569::AID-CNCR1356%3E3.0.CO;2-D

P1433

P1476

Phase II study of gemcitabine ...... advanced pancreatic carcinoma.

@en

P2093

A F Shields

http://www.w3.org/2001/XMLSchema#string

D Weaver

http://www.w3.org/2001/XMLSchema#string

L K Heilbrun

http://www.w3.org/2001/XMLSchema#string

M M Zalupski

http://www.w3.org/2001/XMLSchema#string

P A Philip

http://www.w3.org/2001/XMLSchema#string

P Arlauskas

http://www.w3.org/2001/XMLSchema#string

R Chaplen

http://www.w3.org/2001/XMLSchema#string

V Adsay

http://www.w3.org/2001/XMLSchema#string

V K Vaitkevicius

http://www.w3.org/2001/XMLSchema#string

P2860

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Reporting results of cancer treatment

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

P304

569-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/1097-0142(20010801)92:3<569::AID-CNCR1356>3.0.CO;2-D

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11505401

http://www.w3.org/2001/XMLSchema#string

P921